SEB Asset Management’s ImmunityBio IBRX Stock Holding History

SEB Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$23.1M	Hold	2,447,150	–	–	0.09%	195
2026 Q2	$21.4M	Hold	2,447,150	–	–	0.08%	212
2026 Q1	$18.8M	Buy	+2,447,150	New	+$16.8M	0.08%	210

Other funds holding IBRX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

SEB Asset Management's IBRX Position: Q3 2026 in Review

SEB Asset Management held its ImmunityBio (IBRX) position steady in Q3 2026 at 2,447,150 shares worth $23.1M. The position accounts for 0.09% of the portfolio, ranked #195.

SEB Asset Management first reported a position in IBRX in Q1 2026 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

SEB Asset Management held 2,447,150 shares of ImmunityBio worth $23.1M as of Q3 2026.
SEB Asset Management left its ImmunityBio share count unchanged in Q3 2026.
ImmunityBio made up 0.09% of SEB Asset Management's portfolio in Q3 2026, its #195 holding.
SEB Asset Management first reported a position in ImmunityBio in Q1 2026 and has held it in 3 quarters since.
321 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on SEB Asset Management's 13F filing for Q3 2026, filed 4 Nov 2026.